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European Training Network in Digital
Medical Imaging for Radiotherapy
(ENTERVISION)
Manjit Dosanjh*, Manuela Cirilli and Sparsh Navin
CERN, Geneva, Switzerland
Between 2011 and 2015, the ENTERVISION Marie Curie Initial Training Network has
been training 15 young researchers from a variety of backgrounds on topics ranging
from in-beam Positron Emission Tomography or Single Particle Tomography techniques,
to adaptive treatment planning, optical imaging, Monte Carlo simulations and biological
phantom design. This article covers the main research activities, as well as the training
scheme implemented by the participating institutes, which included academia, research,
and industry.
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INTRODUCTION
Cancer is amajor societal issue, and by 2030 its global incidence is expected to increase bymore than
75% in developed countries and by more than 90% in developing countries (1). A major challenge
for cancer therapy is the complex andmultifaceted nature of the disease, which calls for personalized
treatments and an ever-expanding set of approaches in the oncologists’ toolbox. Radiotherapy (RT)
has been used to treat tumors for more than a century, and still plays a major role in oncology: today,
50% of cancer patients receive RT, half of themwith curative intent and is second only to surgery as a
primary cure. At present, themainstay of RT is photon therapy: this has become highly sophisticated,
with methods like image-guided RT, intensity-modulated RT, stereotactic radiosurgery.
Despite the technological advances in RT approaches, the underlying dose depositionmechanism
will always be the same: for photons, the deposited energy falls off exponentially as the photon beam
traverses the body (except in the case of broad beams since scattering produces a departure of the
attenuation from the exponential behavior). This makes it difficult to protect neighboring healthy
tissues during treatment, which is an issue for deep lying tumors, tumors in/near critical organs, and
pediatric tumors.
This is why RT with protons and other ions, known as Hadron Therapy (HT), has been proposed:
in this case, most of the energy of the therapeutic beam is deposited at the end of its range in a
characteristically peaked distribution (the Bragg peak), sparing the healthy tissue on the way to and
beyond the tumor target.
The use of highly conformal dose distributions to improve the clinical outcomes of RT can be
a double-edged sword. First, the target volume definition must be extremely accurate: if this is
not the case, some tumor regions will not only receive a lower dose, as it also happens in RT
with photons, but might not be irradiated at all, due to the steep dose gradients with protons
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and other ions. Temporal anatomic variations and organ motion
have a more significant adverse influence on dose distributions
in HT compared to RT with photons, making advanced imaging
techniques a prerequisite for successful HT.
Independent studies carried out in Austria, France, Germany,
Italy, and Sweden under the umbrella of the European Network
for Light Ion Hadron Therapy (ENLIGHT) (2) provided evidence
that 10–20% of RT cases may benefit from HT (3): these were
conservative estimates, and therefore the actual numbers could be
even higher.
While it is clear that photons will remain the backbone of RT,
it is timely that the superior dose profiles of protons and carbon
ions are fully exploited in clinical practice. Besides the need for
clinical trials, the scientific community has strongly advocated
for technology developments that would bring the current HT
technology to the high standards of modern photon therapy.
Medical imaging is a key area to ensure the full exploitation
of the potential of HT, in particular through quality assurance
during treatment.Moreover, as new treatment centers are opening
throughout Europe, there is an increasing demand for qualified
experts in the multidisciplinary domains connected to HT. These
issues were addressed by the ENTERVISION training project, a
Marie Curie Initial Training Network aimed at educating young
researchers in online 3D digital imaging for HT.
THE EUROPEAN TRAINING NETWORK IN
DIGITAL MEDICAL IMAGING FOR
RADIOTHERAPY (ENTERVISION)
The ENTERVISION Marie Curie Initial Training Network was
funded by the European Commission (EC) and launched in 2011,
with the aim of educating young researchers in advanced medical
imaging techniques for quality assurance of HT. Ten academic
institutes and research centers of excellence, and a leading Euro-
pean company in HT (see Table 1), recruited 15 researchers from
a variety of academic backgrounds over the course of 4 years (see
Figure 1).
The ENTERVISION researchers were assigned individual
research projects on topics ranging from in-beam Positron Emis-
sion Tomography (PET) or Single Particle Tomography tech-
niques to adaptive treatment planning, optical imaging, Monte
Carlo (MC) simulations, and biological phantom design. The
majority of the researchers were also enrolled in a PhD program
at a partner University, and a personalized career development
plan was established by their supervisors for each researcher. In
addition, the researchers took part in the network-wide training
organized several times a year, offering a diversified portfolio
of scientific courses, complemented by specific courses aimed at
developing soft skills such as leadership and CV writing.
A unique feature of the ENTERVISION project was its con-
nection with the EC-funded R&D project ENVISION, aimed
at developing solutions for quantitative real-time non-invasive
monitoring of HT for stationary and moving organs, accurate
determination of delivered dose, and fast feedback to the Treat-
ment Planning System (TPS) for optimal adaptation strategies.
In fact, ENVISION acted as a “hands-on” training platform for
the Marie Curie researchers, who had the opportunity to interact
TABLE 1 | ENTERVISION partners: this table lists the Institutes, Universities,
and companies participating to ENTERVISION.
Acronym Full name Country
CERN European Organization for Nuclear Research Switzerland
CNRS Centre National pour la Recherche Scientifique France
GSI GSI Helmholtzzen-trum für
Schwer-ionenforschung GmbH
Germany
CSIC Agencia Estatal Consejo Superior de
Investigaciones Científicas
Spain
INFN Istituto Nazionale di Fisica Nucleare Italy
UCAM University of Cambridge UK
TUD Technische Universität Dresden Germany
TERA TERA Foundation Italy
IBA Ion Beam Applications Belgium
UCBL Université Claude Bernard Lyon 1 France
UKL-HD Universitätsklinikum Heidelberg Germany
directly with senior scientists working at the forefront of research
in quality assurance for HT.
The ENTERVISION researchers also benefited from the
involvement in the ENLIGHT network. Throughout the project,
the trainees have been encouraged to build a multidisciplinary
network: this will not only help themwith their future careers, but
will ultimately improve the transfer of knowledge and collabora-
tion between the various disciplines of cancer treatment.
Detailed Research Program of
ENTERVISION
The superior dose distribution of protons and other ions with
respect to photons can be a double-edged sword if a series of
factors (target volume definition, anatomical variations, organ
motion) are not accurately determined and taken into account.
A three-dimensional non-invasive imaging technique for real-
time monitoring of the delivered dose is highly desirable,
and several efforts toward this goal have been pursued within
ENTERVISION.
At present, themost advancedmethod forHTquality assurance
is PET. The use of heavy scintillating crystals coupled to silicon
photomultipliers (SiPM) is one of the most promising solutions
for future PET scanners. Developments in the field of particle
detectors are focused on the use of time of flight (TOF) informa-
tion that aims to improve the sensitivity by improving the signal
to noise ratio.
ENTERVISION tackled the development of a characterization
chain to measure the rising time profiles of signals in scintillating
crystals used both for PET and high-energy physics (4). A rise-
time measurement bench has been set up, where crystals are
irradiated with a 511 keV gamma source, and the light produced is
detected by a photomultiplier. In order to investigate the effect of
thermalization inside the lattice, excitations at two lower energies
are also foreseen. A pulsed X-ray machine excites the crystal
with 20 keV photon pulses, and scintillation photons are collected
with a streak camera system. The crystals are also exposed to
20 eV excitation energies at a vacuum ultraviolet (VUV) laser
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FIGURE 1 | Distribution of ENTERVISION researchers per nationality and recruiting institute.
driven facility. This measurement chain allows complete access to
thermalization lengths. Simulations in Geant4 (5) drive the choice
of interesting crystal samples and set-up geometries.
Alternative detector choices have also been explored. One of
the ENTERVISION researchers built a TOF–PET demonstrator
with Multigap Resistive Plate Chambers (MRPCs) (6), achieving
a preliminary time resolution of 240 ps sigma, and worked on a
proton range telescope, developing an FPGA firmware to allow
high rate acquisition (one million event per second) (7). They
collaborated with another ENTERVISION researcher in order to
prove the feasibility of distributing clocks over aMicroTCA-based
optical fiber network, in order to synchronize electronic front-end
boards at the pico-second scale. This would allow to perform TOF
over a large-scale system dedicated to in-beam PET.
One of the challenges in using PET for HT monitoring, is to
evaluate the motion-influenced artifacts. Within the framework
of ENTERVISION, the influence of various motion parameters
(peakiness, the ratio of inspiration and expiration, frequency,
amplitude, drift, and parameter combination) was investigated
through 40 experiments with radioactive sources performed at the
GSI in-beamPET installation. 4DPET imageswere reconstructed,
compared, and evaluated. The lateral field position and the par-
ticle deposition depth were studied with irradiated phantom
experiments. PET artifacts caused by special respiratory motion
cases (e.g., larger peak to peak amplitude) were also investigated.
A potential artifact-compensation method was proposed, and a
preliminary trial was conducted (8).
Single-particle imaging, i.e., detection of prompt photons, pro-
tons, or neutrons also resulting from nuclear interactions in the
tissues, is emerging as a promising modality for dose monitor-
ing during HT. ENTERVISION focused on improving prompt
photon detection in the clinical scenario, through the develop-
ment and test of gamma cameras, with both passive and active
collimation systems.
One of the research projects carried out detailed comparisons
between a multi-parallel-slit and a knife-edge slit collimator con-
figuration (9). Detailed MC simulations allowed the setting of
guidelines for choosing the optimal configuration of both camera
types for various trade-offs between efficiency and spatial reso-
lution. Measurements with a dedicated detector concept demon-
strated, for the first time the capability of acquiring images at
full clinical beam current, and further validated the results of
simulation. Prototypes for both collimator types have been built
and tested.
Active collimation systems (Compton cameras) have been also
explored in depth. The ENTERVISION researchers assembled
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and tested a variety of detector geometries,materials, and read-out
schemes. One of these is a three-layer Compton telescope based
on continuous LaBr3 crystals and SiPM. The third layer has been
completed recently, and included a new type of SiPM to increase
the active area. The larger active area and a specific bias operating
voltage for a single SiPM array brought an improvement of the
energy resolution (10).
In parallel, a Compton camera has been developed and exten-
sively tested in various beam conditions. Lutetium oxyorthosili-
cate (LSO) and bismuth germinate (BGO) commercial PET block
detectors have been intensively tested and analyzed at different
accelerators, in order to compare their performance and choose
the absorber material. A considerable effort was made to improve
the robustness and speed of themulti-threaded customdata acqui-
sition system (DAQ) and to develop a platform for fast analysis. A
prompt gamma-ray timing method for in vivo range verification
has been proposed and tested at a clinical proton therapy facility,
showing the great potential of this timing technique, with low
footprint and cost and fast range retrieval (11).
In this variegated detector landscape, one ENTERVISION
project aimed at developing a multi-purpose DAQ suitable for
different medical imaging set-ups. The mezzanine boards work
flawlessly, and the firmware is finished, tested and working. This
firmware is intended to serve as a framework for detector develop-
ers, providing all the necessary tools to implement a full-featured
DAQ without dealing with the board’s complexity, but by just
writing the specific application VHDL and C code needed. Com-
patibility at a physics level has been verified with different read-
out boards, while firmware-level compatibility is undergoing. In
its current state, the DAQ system can be used in many different
scenarios, from simple demonstrators to full featured imaging
systems (12).
Highly realistic calculation models and fast simulation codes
are required for most of these quality assurance tools. The high
sensitivity of HT to motion and changes in patient anatomy
calls for adaptive treatment delivery, where the delivered dose is
actively monitored. Fast dose calculation, specifically recalcula-
tion of an existing treatment plan in modified anatomies, consti-
tutes a crucial component in such a system. Also, the interaction
of the incoming therapeutic beam with human tissues leads to
the production of nuclear fragments and secondary light particles;
hence, an accurate estimate of the dose deposited in the cancerous
and healthy tissues requires sophisticated simulation tools based
on nuclear reaction models. The validity of such models has to
be assessed through extensive comparisons with as many sets of
experimental data as possible.
One of the ENTERVISION research projects (13) focused on
improving the nuclear models for carbon ion break-up. In partic-
ular, the researcher had the opportunity to work in collaboration
with iThemba LABS where an experiment (14) with 33MeV/n
12C ions on C, Au, Nb, and Polyethylene targets has been carried
out. This experiment is the only one that took data studying
in correlation all the fragments produced by the quasi elastic
breakup of 12C in 8Be and 4He. Studying exclusively such a
process is of particular interest becausemany experiments showed
a broad peak in the 4He production with an energy per nucleon
close to the beam energy. Moreover, as the 8Be decay almost
immediately in two 4He, this is the only way to disentangle the
He4 produced directly from 12C and from Be8 as intermediate
state. Additionally, such a unique study sets a robust benchmark
for future models and MC simulations. Unusual features in the
energy distributions of the fragments suggest an H contamination
of the targets, a hypothesis confirmed by a second experiment
with a polyethylene target. The contribution of H contaminants
to carbon break-up experiments has been studied, modeled, and
included in the FLUKA (15) simulation code, and will be available
for future studies. It will be useful especially in the simulation
for the proton therapy, as it will more accurately simulate the
production of high linear energy transfer (LET) particles.
ENTERVISION also contributed to the simulation for INSIDE
(16), a multimodal monitoring system for the assessment of HT
accuracy. One of the researchers developed and benchmarked
various FLUKA-based simulations for different scopes. The exper-
imental set-up for a beam test, where prototype detectors and
electronics were evaluated, was simulated. The MC prediction
was found in good agreement with data, and the code could
then be used for the simulation of the full-size detector. Another
important aspect was the evaluation, through the simulation of
realistic treatment conditions, of the radiation damage induced on
the detector by the neutrons produced during patient irradiation.
The lifetime of the INSIDE detectors was thus estimated to be
at least 5 years. Finally, the specific treatment plan of a patient
irradiated at CNAO was simulated using FLUKA, and the results
were compared with the commercial TPS used at the facility.
The isodose distributions were found in good agreement, and the
simulation could then be used to evaluate the Relative Biological
Effectiveness (RBE) during treatment.
As prompt gamma monitoring is emerging as a promising
imaging modality to monitor the range of the particles used to
treat tumors, it is of the utmost importance to have an accurate
description of the physical models used in MC tools for modeling
the emission of prompt gammas. ENTERVISION performed an
extensive and comprehensive analysis of several experiments, in
order to create a large set of data to benchmark simulations:
these included nine experiments with homogeneous targets such
as water and polymethylmethacrylate (PMMA) and three experi-
ments with inhomogeneous targets such as PMMA with a Teflon
piece or a lung-equivalent material, performed at several exper-
imental and clinical facilities around Europe and involving dif-
ferent targets, detectors, and set-ups. A real-size prototype for
prompt gamma monitoring was developed and optimized, focus-
ing on obtaining the best possible precision in the retrieval of the
ion range inside the patient and, at the same time, on providing
additional data for comparison with simulations (17).
One of the ENTERVISION researchers participated to an
experiment performed in collaboration with University La
Sapienza (Rome) where PMMA phantom was irradiated by
220MeV/u carbon-ions (18). The primary ions outgoing from
the exit window were monitored with a plastic scintillator, and
two arms were placed at 90° on each side of the phantom. The
energy spectra of the prompt-γ produced by interaction of the 12C
ions with PMMA target have been measured, and the prompt-γ
rates per incident 12C values for the two measured angles were
compared and found in agreement. The data were compared
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with MC simulations performed with Geant4, using two different
models: the QuantumMolecular Dynamics (QMD)model of ion-
ion collisions and the Binary Cascade light ion model (BIC).
An acceptable agreement, both qualitative and quantitative, was
obtained between energy spectra (experimental and simulated)
and prompt-γ rates, especially for QMD model. Therefore, this
study allowed confirming that the QMD model is more accurate
than BIC model to reproduce both γ-yields values and γ-spectra
as it is the case for charged particles. This originates from the fact
that BIC does not take into account properly inelastic scattering
processes between ions like (12C+ 12C) and (12C+ 16O), and
also neutron scattering.
ENTERVISION also investigated how graphics processing
units (GPUs) can be used to speed up analytical dose calculation
for HT (19). Initially, a prototype for a simple dose calculation
engine was implemented in Matlab together with a graphical user
interface (GUI) and the necessary facilities to open Computed
Tomography (CT) images in the Digital Imaging and Communi-
cations in Medicine (DICOM) format. The simple dose calcula-
tion engine was subsequently implemented to run on GPU and
an interface between the GPU code and the GUI was created to
allow data to be loaded, stored and analyzed in Matlab, but the
calculation to be carried out on a GPU. Following this proof-of-
principle study, the work began to create an efficient parallel GPU
implementation of the widely used pencil beam algorithm. The
implementation was tuned and validated through comparisons
between data and MC simulations. The results produced by the
GPU implementation showed the same level of accuracy as the
dose distribution calculated by the analytical algorithm provided
with the commercial TPS used for the treatment. The sub-second
calculation times also compared very favorably with those found
in the literature, and were short enough to allow for on-line dose
calculation applications. Finally, initial work was done to inves-
tigate a novel method for analytical dose calculation for proton
therapy that would be suitable for parallel implementation.
On the clinical side, weekly 4D CT datasets (9 Non-Small Cell
Lung Cancer (NSCLC) patients representing 70 weekly 4D CT
datasets) from the University of Texas MD Anderson Cancer
Center were used to investigate the impact of several parameters
on dose delivery, target coverage and homogeneity, to eventually
allow recovery for dose delivery errors caused by intra- and inter-
fraction motion. Gating plans (including 4D calculations) were
simulated with the GSI treatment planning software TRiP4D (20).
Optimization was performed with the first week of each patient
using a range-corrected internal target volume (ITV) on states
of the moving tumor. The resulting plans were then used for all
following weeks. In-depth studies showed that the combination
of ITV, isotropic margins, and range margins yielded the best
results in terms of target coverage, even though this led to the
irradiation of a higher portion of normal tissue. Finally, simu-
lations using one, two, or three fields were performed; for each
case, results obtained using ITV only and ITV with additional
isotropic and rangemargins were compared. The best results were
obtained using three fields combined to additional isotropic and
range margins in terms of target coverage. Using several fields
also permitted the reduction of high dose delivery regions in
normal tissue. Rescanningwill be investigated as a next step to also
explicitly address intra-fractionmotion. Lung contours extraction
is also currently in progress to investigate more precisely the dose
delivered to the tissue surrounding the tumor (21).
Finally, ENTERVISION also tackled issues related to biological
and physical doses. Development of clinical treatment protocols
for any type of cancer RT is dependent on the availability of
high quality information on the biological efficacy of radiation
doses using a range of beam qualities. This is true especially in
HT. In order to gain robust data for use in clinical protocols,
multiple cell irradiation experiments must be performed at dif-
ferent dose points, using a range of generic and patient specific
tumor cell lines. It is important to be able to verify quickly the
biological effects of complex dose distributions in homeomorphic
phantoms, alongside measurements of physical dose. A dedi-
cated phantom was designed, tested, and optimized to correctly
correlate the biological and physical dose distributions (22).
In this context, specific software for individual cell recogni-
tion for microbeam targeting and tracking post-irradiation was
developed (23). Bright-field illumination microscopy was chosen
as an imaging method in order to avoid potential toxicity from
fluorescence excitation. However, the obtained images of cells
are characterized by a high degree of complexity since the spe-
cialized cell dishes used for microbeam irradiation exhibit highly
inhomogeneous optical properties. A cell recognition pipeline has
been established using digital image processing techniques and
principles from statistics and cluster analysis. This pipeline is
able to recognize cellular structures avoiding the majority of the
substrate features. It has been tested on both polypropylene and
plastic substrates, and in various cell lines including V79 Chinese
hamster cells, T98G and U251 human glioblastoma cells.
Additionally, initial time-lapse data have been obtained so as
to follow the cells’ life post-irradiation. The biological end-point
is the maintenance of cells’ clonogenic ability when irradiated
with high-LET radiation using charged particle microbeams. Cell
tracking has been applied based on the topological correlation of
cells and cell divisions can be effectively detected when cells are
separated. Location feedback from frame to frame has been inte-
grated in order to correct false cell detection or linking. The pro-
cess can be used as a near real-time application in electrostatic cell
irradiation. Currently, the software can effectively recognize and
irradiate roughly 1,200 cells when real-time tracking is needed,
while this number can be increased tomore than 2,500 whenGPU
is used. If real-time tracking is not necessary, then the number
of cells capable of irradiation and tracking is only limited by the
mechanical properties of the end-station microscope.
Training Program of ENTERVISION
Network-wide events and training courses were organized
throughout the duration of the project. They served the dual
purpose of educating the researchers and of creating occasions for
them to meet, connect with each other, and establish an extensive
professional network with the leading experts in the field.
Courses were aimed at building the researchers’ scientific
knowledge, as well as at enhancing their communication and
leadership skills (see Table 2). The ENTERVISION techni-
cal training portfolio included detectors for medical imag-
ing, electronics, Treatment Delivery Systems, and dosimetry.
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TABLE 2 | ENTERVISION network-wide training courses.
Course title Trainers and
organizers
Basic training ENTERVISION training course: beam
production and delivery, hands-on accelerator,
treatment planning, dosimetry, radiobiology basics,
particle therapy physics
GSI
UKL-HD
ENTERVISION Summer School in Lyon: from physics to
medical imaging
UCBL
CNRS
ENTERVISION Leadership Development Course UCAM
University of Surrey
Evolve Leadteam Ltd
Hands-on detectors and electronics course CSIC
IFIC Valencia
Industrial processes IBA
CV writing CERN
Viva Consult
Intellectual Property CERN Knowledge
Transfer Group
As health applications need industrial support to be deployed suc-
cessfully in hospitals and clinics, a course on industrial processes
was also run. A course on Intellectual Propertymanagementmade
the young researchers aware of the valorization chain for their
scientific results. The ENTERVISION researchers also had the
opportunity to join the courses on the impact of gantries and
imaging on HT techniques run by a previousMarie Curie Actions
Initial Training Network, PARTNER.
Soft-skills courses tackled leadership, curriculum writing, and
communication. The project has been widely disseminated, and
the researchers have been encouraged and motivated to take part
in outreach activities, at their home institute or elsewhere, includ-
ing video interviews (24). In September 2013, several ENTER-
VISION researchers came to CERN to actively participate in the
activities for the European Researchers’ night and the laboratory’s
Open Days. ENTERVISION also co-sponsored a panel at the
EuroScience Open Forum (ESOF) 2014 in Copenhagen chaired
by the project coordinator on “Everything you wanted to know
about cancer but were afraid to ask.”
The researchers have also been attending the annual meetings
of the ENLIGHT network and of the other EC-funded projects
run under the ENLIGHT umbrella (in particular of ENVISION).
In these occasions, they have presented their work and listened to
and interacted with the experts in the HT field, leading to unique
learning and networking opportunities.
CONCLUSION
ENTERVISION has trained 15 researchers in fields connected
to advanced medical imaging techniques for quality assurance
during cancer treatment with HT. The researchers have formed
a close-knit network, which they are exploiting to their advantage
now and for the future. A number of them have already used the
contacts they established during ENTERVISION to secure new
positions as soon as they finished their Marie Curie projects.
In 2013, ENTERVISION has been chosen as “a success story
illustrating the good use of European funds for research” and
“as a flagship project for Marie Curie Actions for the promo-
tion of the H2020 program, as a so-called ‘gold project.”’ The
EC Directorate-General for Research and Innovation chose 37
projects in total from the previous funding scheme (FP7), with
ENTERVISION being the only project representing the Marie
Curie Actions. In the same year, ENTERVISION was featured
in a press release from the EC to mark the visit to CERN of the
EU Commissioner for Education, Culture, Multilingualism and
youth.
A number of highly valuable and interesting results have been
obtained within the framework of ENTERVISION, as proved by
the papers published in this special issue. In addition, 30 posters,
20 oral presentations, and 35 publications featured in interna-
tional conferences and journals. ENTERVISION researchers took
part in the European Researcher’s Night programme and CERN
Open days in 2013, and contributed to the publication of Accas-
tampato (25).
AUTHOR CONTRIBUTIONS
MD – Project proposer and coordinator of the ENTERVISION
and ENVISION projects. MC – ENVISION technical coordinator
and overall Communication and Dissemination officer. SN –
ENTERVISION dissemination and technical coordinator.
ACKNOWLEDGMENTS
The authors wish to thank all the ENTERVISION researchers,
their supporting Institutes, and their supervisors for four intense
years of scientific activity and networking.
FUNDING
ENTERVISION was funded by the European Commission under
Grant Agreement n. 264552.
REFERENCES
1. Bray F, Jemal A, Grey N, Ferlay J, Forman D. Global cancer transitions accord-
ing to the human development index (2008–2030): a population-based study.
Lancet Oncol (2012) 13(8):790–801. doi:10.1016/S1470-2045(12)70211-5
2. Dosanjh M, Cirilli M, Greco V, Meijer AE. The European network for light
ion hadron therapy. J Health Phys (2012) 103(5):674–80. doi:10.1097/HP.
0b013e3182606520
3. Glimelius B, Ask A, Bjelkengren G, Björk-Eriksson T, Blomquist E, Johansson
B, et al. Number of patients potentially eligible for proton therapy. Acta Oncol.
(2005) 44(8):836–49. doi:10.1080/02841860500361049
4. Di Vara N. Study of Time Profiles of Heavy Scintillating Crystals. Ph.D. thesis,
Univeristy of Milano Bicocca, Milan (2014).
5. Agostinelli S, Allison J, Amako K, Apostolakis J, Araujo H, Arce P. Geant4 –
a simulation toolkit. Nucl Instrum Methods Phys Res A (2003) 506(3):250–303.
doi:10.1016/S0168-9002(03)01368-8
6. Amaldi U, Borghi G, BucciantonioM, Kieffer R, Samarati J, Sauli F, et al. Devel-
opment of TOF-PET detectors based on the multi-gap resistive plate chambers.
Nucl Instr Methods A (2015) 778:85–91. doi:10.1016/j.nima.2015.01.018
7. Bucciantonio M, Amaldi U, Kieffer R, Sauli F, Watts D. Development of a fast
proton range radiography system for quality assurance in hadrontherapy. Nucl
InstrumMethods Phys Res A (2013) 732:564–7. doi:10.1016/j.nima.2013.05.110
Frontiers in Oncology | www.frontiersin.org December 2015 | Volume 5 | Article 2656
Dosanjh et al. ENTERVISION Overview
8. Tian Y, Stützer K, Enghardt W, Priegnitz M, Helmbrecht S, Bert C, et al.
Technical note: experimental investigation of irregular motion impact on 4D
PET based particle therapy monitoring. Phys Med Biol.
9. Smeets J, Roellinghoff F, Prieels D, Stichelbaut F, Benilov A, Busca P, et al.
Prompt gamma imaging with a slit camera for real-time range control in proton
therapy. Phys Med Biol (2012) 57(11):3371–405. doi:10.1088/0031-9155/57/11/
3371
10. LlosáG, Cabello J, Callier S, Gillam JJ, LacastaC, RafecasM, et al. First Compton
telescope prototype based on continuous LaBr3-SiPM detectors.Nucl Inst Meth
Phys Res Sec A (2013) 718:130–3. doi:10.1016/j.nima.2012.08.074
11. Golnik C, Hueso-González F, Müller A, Dendooven P, Enghardt W, Fiedler
F, et al. Range assessment in particle therapy based on prompt γ-ray timing
measurements.PhysMed Biol (2014) 59(18):5399–422. doi:10.1088/0031-9155/
59/18/5399
12. Abellan C, Cachemiche J-P, Rethore F, Morel C. A data acquisition system
for medical imaging. Advancements in Nuclear Instrumentation Measurement
Methods and their Applications (ANIMMA). (2013). p. 1–7.
13. Mancini C. Analysis and Interpretation of Carbon Ion Fragmentation in
the Bragg Peak Energy Range. Ph.D. thesis, University of Roma Tre, Rome
(2015)
14. Förtsch SV, Mira J, Smit FD, Steyn GF, Bassini R, Cowley AA, et al. Binary
projectile fragmentation of 12C at an incident energy of 33.3MeV/nucleon. 12th
International Conference on Nuclear Reaction Mechanisms, June 15–19, 2009.
Varenna: Villa Monastero (2009). p. 545–52
15. Ferrari A, Sala PR, Fasso A, Ranft J. FLUKA: A Multi-Particle Transport Code,
CERN-2005-10 (2005), INFN/TC_05/11, SLAC-R-773. (2005).
16. Marafini M, Attili A, Battistoni G, Belcari N, Bisogni MG, Camarlinghi N,
et al. The INSIDE Project: innovative solutions for in-beam dosimetry in
hadrontherapy, Acta Physica Polonica. Proceedings of II Symposium on Positron
Emission Tomography. (Vol. 127). Poland: Jagiellonian University of Krakov
(2015).
17. Pinto M, Dauvergne D, Freud N, Krimmer J, Letang JM, Ray C, et al.
Design optimisation of a TOF-based collimated camera prototype for online
hadrontherapy monitoring. Phys Med Biol (2014) 59(24):7653–74. doi:10.1088/
0031-9155/59/24/7653
18. Vanstalle M, La Tessa C, Schuy C, Sarti A, Piersanti L, Patera V et al. Detection
of Secondary Particles from 12C Fragmentation in an Anthropomorphic Phantom
for SOBP Position Monitoring. GSI Scientific Report (2011)
19. da Silva J, Ansorge R, Jena R. Efficient scatter-based kernel superposition on
GPU. J Parallel Distrib Comput (2015) 84:15–23. doi:10.1016/j.jpdc.2015.07.003
20. Richter D, Trautmann J, Schwarzkopf A, Kraemer M, Gemmel A, Jaekel O,
et al. 4D Treatment Planning Implementations for TRiP98. GSI Scientific Report
(2010)
21. Brevet R. Optimized Treatment Parameters to Account for Interfractional Vari-
ability in Scanned Ion Beam Therapy of Lung Cancer. Ph.D. thesis, University of
Darmstadt, Darmstadt (2015)
22. Lima TVM, Ciocca M, Ferrari A, Mairani A, Molinelli S, Dosanjh M. Monte
Carlo calculations supporting patient plan verification in proton therapy. Front
Oncol.
23. Georgantzoglou A, Merchant MJ, Jeynes JC, Wéra AC, Kirkby KJ, Kirkby
NF, et al. Automatic cell detection in bright-field microscopy for microbeam
irradiation studies. Phys Med Biol (2015) 60(16):6289–303. doi:10.1088/0031-
9155/60/16/6289
24. Outreach Material. Available from: http://cern.ch/ENTERVISION/news.html
25. Available from: http://www.accastampato.it/en/home/copertina-11/
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be
construed as a potential conflict of interest.
Copyright © 2015Dosanjh, Cirilli andNavin. This is an open-access article distributed
under the terms of the Creative Commons Attribution License (CC BY). The use, dis-
tribution or reproduction in other forums is permitted, provided the original author(s)
or licensor are credited and that the original publication in this journal is cited, in
accordance with accepted academic practice. No use, distribution or reproduction is
permitted which does not comply with these terms.
Frontiers in Oncology | www.frontiersin.org December 2015 | Volume 5 | Article 2657
